Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, January 1999, p. 115-120, Vol. 43, No. 1
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Activity and Diffusion of LY333328 in Experimental Endocarditis
Due to Vancomycin-Resistant Enterococcus
faecalis
Azzam
Saleh-Mghir,1
Agnès
Lefort,1
Yolande
Petegnief,2
Sophie
Dautrey,3
Jean-Marie
Vallois,1
Dominique
Le
Guludec,2
Claude
Carbon,1 and
Bruno
Fantin1,*
Institut National pour la Santé et la
Recherche Médicale, CRI 4 U 002D, and Université Paris
7,1
Service de Biophysique et de
Médecine Nucléaire, Hôpital Bichat, and
Université Paris 7,2 and
Service
de Pharmacie Clinique et des Biomatériaux, Hôpital
Bichat,3 Paris, France
Received 15 April 1998/Returned for modification 22 July
1998/Accepted 6 October 1998
The activity of LY333328 against Enterococcus faecalis
JH2-2, which is susceptible to glycopeptides, and against its
transconjugants E. faecalis BM4281 and BM4316, with VanB
and VanA phenotypes, respectively, was investigated. LY333328 was
active in vitro against the three strains, for which MICs were 2 µg/ml on agar and 0.25 µg/ml in broth. LY333328 was bactericidal in
broth against E. faecalis JH2-2 and BM4281 at a
concentration of 8 µg/ml and against BM4316 at a concentration of
30 µg/ml. The protein binding of LY333328 to rabbit serum was >99%,
and the bactericidal activity of LY333328 in broth was reduced when it
was tested in the presence of 90% rabbit serum. Autoradiographic
studies performed in rabbits with enterococcal endocarditis
showed that 14[C]LY333328 was distributed heterogeneously
throughout cardiac vegetations. In rabbits with aortic
endocarditis, a regimen of 20 mg of LY333328 per kg of body weight
administered intramuscularly twice a day for 5 days after a loading
dose of 40 mg/kg was active against the three strains in vivo
(P < 0.01), whereas vancomycin was not active against
the VanB-type strain and teicoplanin was not active against the
VanA-type strain. We conclude that the activity of LY333328 is not
significantly modified by acquired resistance to glycopeptides in
E. faecalis either in vitro or in experimental endocarditis.
*
Corresponding author. Mailing address: Unité de
Médecine Interne, 100 boulevard du Général Leclerc,
92118 Clichy Cedex 18, France. Phone: 33 1 40 87 58 90. Fax: 33 1 40 87 54 95. E-mail: bruno.fantin{at}bjn.ap-hop-paris.fr.
Antimicrobial Agents and Chemotherapy, January 1999, p. 115-120, Vol. 43, No. 1
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Belley, A., Neesham-Grenon, E., McKay, G., Arhin, F. F., Harris, R., Beveridge, T., Parr, T. R. Jr., Moeck, G.
(2009). Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureus Cells In Vitro. Antimicrob. Agents Chemother.
53: 918-925
[Abstract]
[Full Text]
-
Vouillamoz, J., Moreillon, P., Giddey, M., Entenza, J. M.
(2006). Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci. J Antimicrob Chemother
58: 1208-1214
[Abstract]
[Full Text]
-
Lefort, A., Pavie, J., Garry, L., Chau, F., Fantin, B.
(2004). Activities of Dalbavancin In Vitro and in a Rabbit Model of Experimental Endocarditis Due to Staphylococcus aureus with or without Reduced Susceptibility to Vancomycin and Teicoplanin. Antimicrob. Agents Chemother.
48: 1061-1064
[Abstract]
[Full Text]
-
Cabellos, C., Fernandez, A., Maiques, J. M., Tubau, F., Ardanuy, C., Viladrich, P. F., Linares, J., Gudiol, F.
(2003). Experimental Study of LY333328 (Oritavancin), Alone and in Combination, in Therapy of Cephalosporin-Resistant Pneumococcal Meningitis. Antimicrob. Agents Chemother.
47: 1907-1911
[Abstract]
[Full Text]
-
Lefort, A., Lafaurie, M., Massias, L., Petegnief, Y., Saleh-Mghir, A., Muller-Serieys, C., Le Guludec, D., Fantin, B.
(2003). Activity and Diffusion of Tigecycline (GAR-936) in Experimental Enterococcal Endocarditis. Antimicrob. Agents Chemother.
47: 216-222
[Abstract]
[Full Text]
-
Gerber, J., Smirnov, A., Wellmer, A., Ragheb, J., Prange, J., Schutz, E., Wettich, K., Kalich, S., Nau, R.
(2001). Activity of LY333328 in Experimental Meningitis Caused by a Streptococcus pneumoniae Strain Susceptible to Penicillin. Antimicrob. Agents Chemother.
45: 2169-2172
[Abstract]
[Full Text]
-
Patel, R., Rouse, M. S., Piper, K. E., Steckelberg, J. M.
(2001). Linezolid Therapy of Vancomycin-Resistant Enterococcus faecium Experimental Endocarditis. Antimicrob. Agents Chemother.
45: 621-623
[Abstract]
[Full Text]
-
Lefort, A., Saleh-Mghir, A., Garry, L., Carbon, C., Fantin, B.
(2000). Activity of LY333328 Combined with Gentamicin In Vitro and in Rabbit Experimental Endocarditis Due to Vancomycin-Susceptible or -Resistant Enterococcus faecalis. Antimicrob. Agents Chemother.
44: 3017-3021
[Abstract]
[Full Text]
-
Zeckel, M. L., Preston, D. A., Allen, B. S.
(2000). In Vitro Activities of LY333328 and Comparative Agents against Nosocomial Gram-Positive Pathogens Collected in a 1997 Global Surveillance Study. Antimicrob. Agents Chemother.
44: 1370-1374
[Abstract]
[Full Text]
-
Arthur, M., Depardieu, F., Reynolds, P., Courvalin, P.
(1999). Moderate-Level Resistance to Glycopeptide LY333328 Mediated by Genes of the vanA and vanB Clusters in Enterococci. Antimicrob. Agents Chemother.
43: 1875-1880
[Abstract]
[Full Text]